

Particulars	Standalone Results					Consolidated Results	
	Quarter Ended			Year Ended		Year Ended	
	Mar 2015	Dec 2014	Mar 2014	Mar 2015	Mar 2014	Mar 2015	Mar 2014
	Unaudited*	Unaudited	Unaudited*	Audited	Audited	Audited	Audited
(a) Net sales/income from operations	1475.77	1352.52	1788.19	5670.61	5469.89	5670.61	5469.89
(b) Other operating income	-23.85	29.02	57.33	68.78	200.94	68.78	200.94
1. Total income from operations (net) (a+b)	1451.91	1381.53	1845.52	5739.39	5670.83	5739.39	5670.83
(c) Cost of materials consumed	860.97	815.97	982.65	3517.62	3298.42	3517.62	3298.42
(d) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(e) Changes in inventories of fin. goods, stock-in-pro. & stock-in-trade	126.89	-21.47	136.05	92.24	-88.42	92.24	-88.42
(f) Employee benefits expense	188.28	167.37	233.55	763.15	796.76	763.15	796.76
(g) Depreciation and amortization expense	184.87	14.74	226.11	606.60	905.91	606.60	905.91
(h) Other expenses	267.79	252.03	272.93	1024.62	1097.84	1024.71	1097.84
2. Total expenses (c+d+e+f+g+h)	1628.79	1228.64	1851.29	6004.22	6010.50	6004.31	6010.50
3. Profit/ Loss(-) from operations before other income and finance costs (1-2)	-176.88	152.90	-5.77	-264.83	-339.67	-264.92	-339.67
4. Other income	126.93	145.94	-47.87	278.81	56.78	278.81	56.78
5. Profit/ Loss(-) from ordinary activities before finance costs (3+4)	-49.94	298.84	-53.64	13.99	-282.89	13.89	-282.89
6. Finance costs	27.34	35.63	55.51	170.23	212.24	170.23	212.24
7. Profit/ Loss(-) from ordinary activities before tax (5-6)	-77.28	263.21	-109.15	-156.24	-495.12	-156.33	-495.12
8. Tax expense	-131.41	0.00	5.56	-131.41	20.36	-131.41	20.36
9. Net Profit/ Loss(-) from ordinary activities after tax (7-8)	54.13	263.21	-114.71	-24.84	-515.48	-24.93	-515.48
10. Extraordinary Items (Loss On Slump Sale of Unit-II)	2.52	-117.36	0.00	-114.84	0.00	-114.84	0.00
11. Net Profit/ Loss(-) after tax and Extraordinary Items (9+10)	56.65	145.85	-114.71	-139.68	-515.48	-139.77	-515.48
12. Minority Interest (for Consolidated Results only)	N/A	N/A	N/A	N/A	N/A	0.00	0.00
13. Net Profit/ Loss(-) after Minority interest (11-12)	N/A	N/A	N/A	N/A	N/A	-139.77	-515.48
14. Paid-up equity share capital (Face Value ₹ 10 Each)	2104.06	2104.06	2104.06	2104.06	2104.06	2104.06	2104.06
15. Reserves excluding Revaluation Reserves as per bal. sheet of prev. year					7241.99		7241.99
16. Basic and Diluted EPS in ₹ before Extraordinary Items (not annualized)	0.26	1.25	-0.55	-0.12	-2.45	-0.12	-2.45
17. Basic and Diluted EPS in ₹ after Extraordinary Items (not annualized)	0.27	0.69	-0.55	-0.66	-2.45	-0.66	-2.45
A1. Public shareholding - Number of shares	10319030	10319030	10319030	10319030	10319030	10319030	10319030
- Percentage of shareholding	49.04%	49.04%	49.04%	49.04%	49.04%	49.04%	49.04%
A2. a) Promoters and Promoter Group Pledged/ Encumbered No. of shares	0	0	0	0	0	0	0
- Percentage of total shareholding of promoters & promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
- Percentage of total share capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
A2. b) Promoters and Promoter Group Non-encumbered No. of shares	10721570	10721570	10721570	10721570	10721570	10721570	10721570
- Percentage of total shareholding of promoters & promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of total share capital of the company	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%
B. Investor Complaints: Pending at the start of the quarter	0			Received during the quarter		1	
Investor Complaints: Disposed off during the quarter	1			Unresolved till end of the quarter		0	

Notes:

- The above results have been audited by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary. Specifically, a sum of ₹ 300.00 lacs put aside in a fixed deposit in the name of the Company, but used to furnish a bank guarantee of the same amount in the name of Ranbaxy Laboratories Limited in an ongoing arbitration proceeding (refer Note 9 below) was booked as an expense under Extraordinary Item in the unaudited financial results for the Quarter Ended 31st December 2014. This sum of ₹ 300.00 lacs has subsequently been removed as an expense and has been reclassified under the head of Contingent Liabilities & Commitments (to the extent not provided for) in the audited statements.
- *The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of that financial year.
- Subsequent to the Shareholders approval dated 04th April 2014, the Company has sold its Unit-II ("Undertaking") situated at Sector III, Pithampur, Dhar (M.P.) as a going concern on a slump sale basis to Ipcal Laboratories Limited ("Buyer"). The Company has received a consideration of ₹ 6400 lacs towards the Business Transfer Agreement ("BTA") as a going concern on a slump sale basis and a fee of ₹ 10 lacs excluding taxes towards the Non Compete Agreement ("NCA") from the Buyer. Both Agreements were executed and made effective on 01st October 2014 and hence the Company has discontinued business from the Unit-II business division from that day. The sold Undertaking of the Company had incurred a Net Loss of ₹ 865.57 lacs in the financial year 2013-14 and has incurred a Net Loss of ₹ 549.76 lacs in the financial year 2014-15 during the 6 months before being sold.
- a) In accordance with the provisions of Schedule II of the Companies Act 2013, in case of fixed assets which have completed their useful life as at 01st April 2014, the carrying value (net of residual value) amounting to ₹ 34.88 lacs (net of deferred tax of ₹ 17.96 lacs) as a transitional provision has been recognized in the retained earnings.
b) For assets acquired prior to 01st April 2014, the carrying value of assets (net of residual value) is depreciated over the remaining useful life as determined from 01st April 2014.
c) Depreciation and amortization expenses for the financial year 2014-15 would be lower by ₹153.42 lacs if the Company had continued with the previous assessment of useful life of such assets.
- During the year, the Company has invested an amount of ₹ 1 lac by purchasing shares of Norfolk Mercantile Private Limited making it a wholly owned subsidiary of the Company.
- During the year, Ranbaxy Laboratories Limited (Petitioner) filed a Petition in the High Court at New Delhi to prevent the Company from selling its Unit-II division situated at Sector III, Pithampur, Dhar (M.P.). To expedite matters, the Company agreed to enter into arbitration proceedings with the Petitioner and furnish a bank guarantee to the tune of ₹ 300.00 lacs in the name of the Petitioner which shall remain live till the final disposal of the arbitration proceedings. The Honorable High Court disposed of the petition without restricting the Company from selling its Unit-II division. In the ongoing arbitration proceedings, the Petitioner has claimed ₹ 3927.64 lacs against the Company and the Company has made a counter claim of ₹ 6001.30 plus legal costs & interest @ 24% per year against the Petitioner. The Company is of the view that no provision is required to be made in the accounts as it expects a favorable outcome of the arbitration proceedings and hence adjustments, if any, will be recorded by the Company on final outcome of the matter. The claim made by the Petitioner against the Company has been disclosed under the head of Contingent Liabilities & Commitments (to the extent not provided for) in the audited statements.
- Consolidated financial results includes financial results of the Company and its wholly owned subsidiary.

Place: Pigdamber, Rau, Indore
Date: 29th May 2015



For ALPA LABORATORIES LIMITED
Mahendra M. S. Chawla, Director

Particulars	Standalone Results		Consolidated Results	
	Mar 2015	Mar 2014	Mar 2015	Mar 2014
	Audited	Audited	Audited	Audited
(a) Share capital	2104.06	2104.06	2104.06	2104.06
(b) Reserves and surplus	6551.95	6726.50	6551.95	6726.50
A1. Sub-total - Shareholders' funds (a+b)	8656.01	8830.56	8656.01	8830.56
A2. Minority Interest (for Consolidated Results only)	N/A	N/A	0.00	0.00
(c) Long-term borrowings	0.00	420.07	0.00	420.07
(d) Deferred tax liabilities (net)	0.00	140.02	0.00	140.02
(e) Other long-term liabilities	50.62	50.62	50.62	50.62
A3. Sub-total - Non-current liabilities (c+d+e)	50.62	610.70	50.62	610.70
(f) Short-term borrowings	2857.17	1605.15	2857.17	1605.15
(g) Trade payables	902.82	1061.80	902.82	1061.80
(h) Other current liabilities	238.62	489.28	238.62	489.28
(i) Short-term provisions	125.53	73.50	125.53	73.50
TOTAL - EQUITY AND LIABILITIES (A1+A2+A3+A4)	12830.78	12670.99	12830.78	12670.99
(j) Fixed assets	479.64	7311.43	479.64	7311.43
(k) Capital work-in-progress	7.36	0.00	7.36	0.00
(l) Goodwill (for Consolidated Results only)	N/A	N/A	0.00	0.00
(m) Non-current Investments	1011.00	0.00	1011.00	0.00
(n) Deferred tax assets (net)	9.35	0.00	9.35	0.00
(o) Long-term loans and advances	61.79	83.84	61.79	83.84
B1. Sub-total - Non-current assets (j+k+l+m+n+o)	1569.13	7395.27	1569.13	7395.27
(p) Inventories	751.74	1300.44	751.74	1300.44
(q) Trade receivables	2447.79	2008.02	2447.79	2008.02
(r) Cash and cash equivalents	7212.87	1046.15	7212.87	1046.15
(s) Short-term loans and advances	691.84	843.08	691.84	843.08
(t) Other current assets	157.39	78.03	157.39	78.03
B2. Sub-total - Current assets (p+q+r+s+t)	11261.64	5275.72	11261.64	5275.72
TOTAL - ASSETS (B1+B2)	12830.78	12670.99	12830.78	12670.99

Place: Pigdamber, Rau, Indore
Date: 29th May 2015



For ALPA LABORATORIES LIMITED

Mahendera M. S. Chawla, Director